ClinicalTrials.gg
RecruitingNCT07753343HIROESUpdated Aug 7, 2026

Identification and Description of Patients With High-risk Non Metastatic RCC

An observational study in Renal Cell Carcinoma, sponsored by University Hospital, Bordeaux. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-07.

Sponsored by University Hospital, Bordeaux · Observational

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
6,109
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Carcinoma, Renal Cell by University Hospital, Bordeaux — 5 open to participants now, 6 under way, 1 of them phase 3. Carcinoma, Renal Cell · University Hospital, Bordeaux.

Started
2026
the only one that year
Observational
4 of 13
1 open now
Registered
13th of 13
by date

Among the 13 studies in Carcinoma, Renal Cell by University Hospital, Bordeaux, this one is the only one that started in 2026, is one of 4 observational ones, and was the 13th registered.

Carcinoma, Renal Cell

2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 396 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

5 of the 13 studies in Carcinoma, Renal Cell by University Hospital, Bordeaux are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Carcinoma, Renal Cell by University Hospital, Bordeaux, or all of them as a file.
02

Study summary

Renal cell carcinoma (RCC) is the 14th most common cancer worldwide. Surgery is the standard of care for localized RCC, however, the risk of recurrence varies widely among patients. Adjuvant pembrolizumab has been shown to improve outcomes after nephrectomy but is associated with substantial toxicity and high costs. This study uses real-world data from the French UroCCR-Chain registry to characterize the natural history, management, and outcomes of non-metastatic RCC in France, with the aim of informing adjuvant treatment decisions

Read the detailed description

Renal cell carcinoma (RCC) is the 14th most common malignant tumour worldwide, with 431,288 new cases reported in 2020. The standard treatment for localised and locally advanced renal tumours is partial or radical nephrectomy. However, 5-year postoperative recurrence-free survival rates vary widely, ranging from 10% to 95%. Currently, there is a lack of reliable, accurate, and up-to-date prognostic models to predict the risk of disease recurrence after surgery.

Recently, the phase 3 clinical trial Keynote 564 demonstrated that adjuvant pembrolizumab, administered for one year following surgery, significantly improves disease-free survival (DFS) and overall survival (OS). Nevertheless, many patients experienced adverse effects, and the high cost of treatment remains a major concern.

Therefore, precise postoperative risk assessment for progression in patients with localised or locally advanced RCC is essential. This enables clinicians to identify candidates most likely to benefit from adjuvant therapy, weigh the potential risks and benefits, and ensure cost-effective use of healthcare resources. In France, pembrolizumab has been available since December 2023-initially through early access programmes and subsequently via marketing authorisation-for patients identified as being at "high risk of recurrence."

However, contemporary real-world data from France remain scarce regarding the accurate characterisation of these high-risk patients and the medical and economic impact of introducing this adjuvant therapy.

The aim of this study is to expand current knowledge on the natural history, management, and clinical outcomes of non-metastatic RCC in France, particularly in the high-risk population, by leveraging data from UroCCR-Chain. This registry, derived from our kidney cancer-specific Health Data Warehouse (UroCCR), is referenced by both the French National Cancer Institute (INCa) and the French National Authority for Health (HAS), and is linked to the French National Health Data System (SNDS).

03

Conditions studied

  • Renal Cell Carcinoma

Keywords

  • renal cell carcinoma (RCC) high-risk RCC
  • real life
  • UroCCR
  • UroCCR-Chain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

see Eligibility Criteria

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients diagnosed with local RCC or high-risk locally advanced RCC,
  • Included in UroCCR register between 1st january 2014 and 31st december 2023,
  • Consenting to participate in UroCCR and UroCCR-Chain registers.

Exclusion criteria

Exclusion Criteria:

  • Patients with disease at inclusion,
  • Patients not linked between UroCCR and SNDS datasources,
  • Patients with hereditary RCC.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
6,109 participants (estimated)
Patient registry
No

Groups and cohorts

  • Overall RCC population

    Patients diagnosed with local RCC or high-risk locally advanced RCC.

    Other: Cohort 1

  • Non clear RCC population

    Non clear RCC population

    Other: Cohort 2

  • Clear RCC population stratified by eligibility based on the Keynote-564 study criteria

    Keynote-564 study criteria: pT2 grade 4, pT3-T4 with any N and any grade, any T with N1, all M0

    Other: Cohort 3

Interventions

  • OtherCohort 1

    Overall RCC Population

  • OtherCohort 2

    Non clear RCC population

  • OtherCohort 3

    Clear RCC population stratified by eligibility based on the Keynote-564 study criteria

06

What researchers measure

Primary outcomes

  1. Description of the natural evolution of the disease in the overall RCC population and in the ncRCC and cRCC subgroups according to the inclusion criteria of the KEYNOTE-564 study.

    Assessment of time to first occurrence of the event of interest (disease-free survival, DFS, local recurrence-free survival, LRFS, or progression-free survival, PFS) or death from any cause (overall survival, OS), whichever occurs first.

    Time frame: From 2014/01/01 to 2023/12/31

  2. Description of the characteristics of the overall RCC population, the ncRCC and ccRCC subgroups, according to whether or not they met the Keynote-564 study eligibility criteria.

    1. Number and proportion (%) of patients eligible for adjuvant therapy among those who underwent surgery for non-metastatic renal cell carcinoma, according to predefined eligibility criteria (ccRCC pT2 grade 4, pT3-T4 of any grade, pTany N1 of any grade, M0). 2. Proportion of high-risk patients relative to the annual incidence of surgically treated renal cell carcinoma. 3. Estimated size of the eligible population extrapolated to the national level (France).

    Time frame: From 2014/01/01 to 2023/12/31

  3. Description of the distribution of UroPredict 2 prognostic risk categories among patients with ccRCC, stratified according to fulfillment of the KEYNOTE-564 eligibility criteria.

    Number and percentage (%) of patients classified as 'Very low risk', 'Low risk', 'Medium risk' and 'High risk' according to UroPredict 2.

    Time frame: From 2014/01/01 to 2023/12/31

  4. Description the natural post-operative course of localised and locally advanced RCC (1)according to the UroPredict 2 classification in the total, ncRCC and ccRCC populations, according to fulfillment of the KEYNOTE-564 eligibility criteria (1)

    Overall Survival (OS) is defined as the time from surgery to death from any cause. Patients will be classified as 'Very low risk', 'Low risk', 'Medium risk' and 'High risk' according to UroPredict 2.

    Time frame: From 2014/01/01 to 2023/12/31

  5. Description the natural post-operative course of localised and locally advanced RCC according to the UroPredict 2 classification in the total, ncRCC and ccRCC populations, according to fulfillment of the KEYNOTE-564 eligibility criteria (2).

    Disease Free Survival (DFS) is defined as the time from surgery until the first documented disease recurrence or death from any cause, whichever occurs first. Patients will be classified as 'Very low risk', 'Low risk', 'Medium risk' and 'High risk' according to UroPredict 2.

    Time frame: From 2014/01/01 to 2023/12/31

  6. Description the natural post-operative course of localised and locally advanced RCC according to the UroPredict 2 classification in the total, ncRCC and ccRCC populations, according to fulfillment of the KEYNOTE-564 eligibility criteria. (3)

    Local recurrence-free survival (LRFS) is defined as the time from surgery until the first documented local recurrence of the disease or death from any cause, whichever occurs first. Patients will be classified as 'Very low risk', 'Low risk', 'Medium risk' and 'High risk' according to UroPredict 2.

    Time frame: From 2014/01/01 to 2023/12/31

  7. Description the natural post-operative course of localised and locally advanced RCC according to the UroPredict 2 classification in the total, ncRCC and ccRCC populations, according to fulfillment of the KEYNOTE-564 eligibility criteria.(4)

    Progression-free survival (PFS) is defined as the time from surgery until the first documented disease progression, recurrence, or death from any cause, whichever occurs first. Patients will be classified as 'Very low risk', 'Low risk', 'Medium risk' and 'High risk' according to UroPredict 2.

    Time frame: From 2014/01/01 to 2023/12/31

  8. Identification of the predictors of favorable response to immunotherapy among high-risk patients with ccRCC meeting the KEYNOTE-564 eligibility criteria who subsequently developed metachronous metastatic recurrence and were treated with immunotherapy.

    Clinical, biological, anatomopathological and molecular factors associated with response to immunotherapy, defined by tumour response status (RC or RP vs SD or PD) in high-risk ccRCC patients according to Keynote 564 who have developed metachronous metastatic recurrence.

    Time frame: From 2014/01/01 to 2023/12/31

  9. Analyse of the care pathways for patients with non-metastatic RCC (total population, the ncRCC population and the ccRCC population)..

    Hospital admissions related to RCC; Surgical procedures, radiotherapy and systemic treatments (including bisphosphonates and denosumab); Diagnostic and follow-up investigations: imaging, laboratory tests, consultations (oncology, urology and others).

    Time frame: From 2014/01/01 to 2023/12/31

  10. Assesment of healthcare resource utilization and associated costs before and after disease recurrence.

    Total reimbursed healthcare costs associated with the management of patients with RCC, before and after disease recurrence.

    Time frame: From 2014/01/01 to 2023/12/31

  11. Estimation of the cost of adjuvant treatment in the high-risk RCC population (taking into account the results of the Keynote 564 trial and the cost of treatment).

    Total cost of adjuvant immunotherapy (pembrolizumab or nivolumab/ipilimumab) in the high-risk RCC population, expressed on a per-patient basis and extrapolated to the target population, incorporating efficacy data from the KEYNOTE-564 trial.

    Time frame: From 2014/01/01 to 2023/12/31

  12. Assesment of the correlation between DFS and OS within the high-risk RCC population.

    Comparison between DFS and OS in the high-risk RCC population.

    Time frame: From 2014/01/01 to 2023/12/31

  13. Assement of the the impact of long-term post-operative use of aspirin on the incidence of disease recurrence (total population, the ncRCC population and the ccRCC population). (1)

    Overall Survival (OS) according to the use of long-term post-operative aspirin.

    Time frame: From 2014/01/01 to 2023/12/31

  14. Assement of the the impact of long-term post-operative use of aspirin on the incidence of disease recurrence (total population, the ncRCC population and the ccRCC population). (2)

    Disease Free Survival (DFS) according to the use of long-term post-operative aspirin.

    Time frame: From 2014/01/01 to 2023/12/31

  15. Assement of the impact of the time to recurrence, as well as associated factors (site of recurrence, number of lesions), on OS.

    OS according to the time to recurrence (early, intermediate or late) and associated factors (site of recurrence, number of lesions).

    Time frame: From 2014/01/01 to 2023/12/31

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Apr 2028, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2026
First posted
Aug 7, 2026
StartActual
Apr 17, 2026
Primary completionEst.
Apr 17, 2028
CompletionEst.
Apr 17, 2028
Last update
Aug 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07753343
Responsible party
Sponsor
First posted
Aug 7, 2026
Start date
Apr 17, 2026
Primary completion
Apr 17, 2028 (estimated)
Completion
Apr 17, 2028 (estimated)
Last update
Aug 7, 2026

Study contacts

Jean-Christophe BERNHARD, Pr
Contact
jean-christophe.bernhard@chu-bordeaux.fr
0033540451179
Gaelle MARGUE, Dr
Contact
Jean-Christophe BERNHARD, Pr
principal investigator · University Hospital, Bordeaux

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion